-
AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow US firm Xilio Therapeutics, Inc. (NASDAQ: XLO). The partnership aims to leverage Xilio’s proprietary technology to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers. Details of the CollaborationXilio, with its proprietary, clinically-validated platform technology…
